List Alan

SEC source: 0000897069-26-000363 · form4.xml · derivative · entry 1

List Alan · CIK 0001858530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,240

Underlying: Common Stock · 156,240 shares

Expires 2036-02-12

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

SEC source: 0000897069-25-000033 · form4.xml · derivative · entry 1

List Alan · CIK 0001858530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,275

Underlying: Common Stock · 51,275 shares

Expires 2035-01-02

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

SEC source: 0000897069-24-002007 · form4.xml · derivative · entry 2

List Alan · CIK 0001858530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2034-02-28

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-002007 · form4.xml · derivative · entry 1

List Alan · CIK 0001858530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2033-01-16

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000950170-24-053113 · ownership.xml · nonDerivative · entry 2

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,488

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.53. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-053113 · ownership.xml · derivative · entry 3

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 981

Underlying: Common Stock · 982 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F5 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0000950170-24-053113 · ownership.xml · nonDerivative · entry 1

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,778

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting of Restricted Stock Units ("RSUs") on March 3, 2024, and subsequent settlement of such vested RSUs on May 1, 2024.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0000950170-24-050769 · ownership.xml · nonDerivative · entry 2

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,796

F4 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.85 to $10.14. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-050769 · ownership.xml · derivative · entry 3

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 868 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F6 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0000950170-24-050769 · ownership.xml · nonDerivative · entry 1

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,034

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on April 26, 2024.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · balance_after: On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split.

SEC source: 0001209191-24-002115 · doc4.xml · nonDerivative · entry 2

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 94,982

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan adopted on September 10, 2021. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

SEC source: 0001209191-24-002115 · doc4.xml · derivative · entry 3

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,988

Underlying: Common Stock · 60,012 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

F4 · derivative.exercise_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001209191-24-002115 · doc4.xml · nonDerivative · entry 1

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,508

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2024.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

SEC source: 0001209191-23-026066 · doc4.xml · nonDerivative · entry 2

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,496

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

SEC source: 0001209191-23-026066 · doc4.xml · derivative · entry 3

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,028

Underlying: Common Stock · 26,027 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001209191-23-026066 · doc4.xml · nonDerivative · entry 1

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,267

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on April 26, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001209191-23-016857 · doc4.xml · nonDerivative · entry 2

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,240

F3 · kind: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

SEC source: 0001209191-23-016857 · doc4.xml · derivative · entry 3

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,890

Underlying: Common Stock · 29,453 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F4 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001209191-23-016857 · doc4.xml · nonDerivative · entry 1

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,713

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on March 3, 2023.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001209191-23-004607 · doc4.xml · derivative · entry 1

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: Award vests in three equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

F2 · derivative.expiration_date: Award vests in three equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001209191-22-026041 · doc4.xml · nonDerivative · entry 2

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,260

F3 · kind: The sale was effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

SEC source: 0001209191-22-026041 · doc4.xml · derivative · entry 3

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,055

Underlying: Common Stock · 26,035 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's Common Stock.

F4 · derivative.exercise_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

F4 · derivative.expiration_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

SEC source: 0001209191-22-026041 · doc4.xml · nonDerivative · entry 1

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,035

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on April 26, 2022.

F2 · price: Each RSU represents a contingent right to receive one share of the Company's Common Stock.

SEC source: 0001209191-22-016664 · doc4.xml · derivative · entry 2

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,343

Underlying: Common Stock · 88,343 shares

Expires not disclosed

F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock.

F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

SEC source: 0001209191-22-016664 · doc4.xml · derivative · entry 1

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,299

Underlying: Common Stock · 140,299 shares

Expires 2032-03-02

F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on March 3, 2023 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

SEC source: 0001209191-21-039300 · doc4.xml · derivative · entry 2

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,090

Underlying: Common Stock · 78,090 shares

Expires not disclosed

F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock.

F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates.

SEC source: 0001209191-21-039300 · doc4.xml · derivative · entry 1

List Alan · CIK 0001858530 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,186

Underlying: Common Stock · 134,186 shares

Expires 2031-06-06

F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 26, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date.